KPV

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal tripeptide sequence of α-melanocyte-stimulating hormone. α-MSH is a 13-amino-acid melanocortin generated from proopiomelanocortin by post-translational processing, more specifically from the ACTH precursor by proteolytic cleavage.

Reviews of the melanocortin family report that this C-terminal tripeptide exerts anti-inflammatory activity similar to, or more pronounced than, full-length α-MSH, and that N-acetylated and C-amidated variants have also been studied.

Mechanism

The transport step is unusually well defined for a peptide of this size. In Caco2-BBE and HT29-Cl.19A human intestinal epithelial cell lines and in human T cells, KPV was shown to act via PepT1, the di- and tripeptide transporter that is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease; KPV was transported into cells by PepT1 and exerted its effects intracellularly. Once inside, it inhibited activation of NF-κB and MAP kinase inflammatory signalling and reduced pro-inflammatory cytokine expression and secretion.

Similar signalling findings appear in skin cells. In human HaCaT keratinocytes exposed to fine particulate matter, KPV restored cell viability, inhibited reactive oxygen species production, blocked ROS-mediated caspase-1 activation, decreased Bax, Bcl-2 and cleaved caspase-3, and reduced IL-1β expression through suppression of NF-κB. Reviews of the wider α-MSH literature report that α-MSH and KPV reduce inflammatory-mediator-induced NF-κB translocation and IL-1β surface binding in human in vitro systems, with MC1R expressed on human keratinocytes and other cutaneous cells.

Evidence status

KPV is not an approved medicine, and no human clinical trial of it is reported in the sources consulted: they state no regulatory status, no trial phase, no indication and no human outcome. The conclusions of the primary work are explicitly tentative — that KPV “might be” a new therapeutic agent for inflammatory bowel disease.

The efficacy evidence is a combination of human cell lines and mouse disease models. A delivery study using hyaluronic-acid-functionalised nanoparticles in a chitosan/alginate hydrogel reported therapeutic effects in a DSS-induced ulcerative colitis mouse model and in vitro cell systems, with no human efficacy, safety, pharmacokinetic or immunogenicity results. The keratinocyte study reported no animal data at all and framed its findings as potential for skin-protective applications.

What the literature does not establish

• No human clinical trial, phase, indication or outcome is reported for KPV in any of the sources consulted.
• The colitis efficacy findings come from a DSS-induced mouse model and cell systems; the sources state they do not establish that the mucosal healing or cytokine effects will occur in humans.
• No receptor mediating KPV activity is identified; PepT1 is a transporter, not a receptor, and the primary study notes its mechanisms of action were unknown at the outset.
• Long-term safety of repeated oral administration is not reported, and the fate of the delivery vehicles in humans is not established.
• Whether effects vary with disease severity, disease location or IBD subtype is not established, and one keratinocyte study does not state the species or cellular composition of the three-dimensional skin model used.

Sources

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (PubMed) — establishes the Lys-Pro-Val sequence, PepT1-mediated entry in Caco2-BBE and HT29-Cl.19A human cells and T cells, NF-κB and MAP kinase inhibition, and the absence of human trial or regulatory data.
• α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs (PMC) — establishes α-MSH as a 13-residue POMC-derived peptide, KPV as its C-terminal tripeptide with comparable or greater anti-inflammatory activity, and the human in vitro NF-κB and IL-1β findings.
• Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles (PMC) — the DSS-induced mouse colitis model results, the explicit absence of human efficacy and safety data, and the stated animal-to-human gaps.
• KPV mitigates keratinocyte apoptosis and inflammation from particulate matter (PubMed) — the human HaCaT keratinocyte findings on ROS, caspase-1, apoptosis-related proteins and NF-κB-dependent IL-1β, with no animal or human trial data.